Te­va and Alvotech's in­ter­change­able Hu­mi­ra biosim­i­lar joins the par­ty

No more wait­ing in the wings. Te­va and Alvotech won ap­proval Fri­day for their Hu­mi­ra biosim­i­lar Sim­lan­di af­ter re­solv­ing man­u­fac­tur­ing is­sues that caused mul­ti­ple re­jec­tions.

The part­ners will launch their in­ter­change­able, high-con­cen­tra­tion Sim­lan­di “im­mi­nent­ly,” they said in a news re­lease. The drug will be up against sev­er­al oth­er biosim­i­lars al­ready on the mar­ket, but Te­va’s CEO Richard Fran­cis isn’t wor­ried about be­ing late to the par­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.